Physician profile
Christopher Michael
NPI 1417978016
$2,018.56
in general payments reported to CMS, 2019-2025
11 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $911 · 2023: $18.13 · 2024: $81.80 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Captiva Spine INC | $981.67 | 2019-2020 | |
| Titan Spine, LLC | $625.00 | 2019 | |
| Medtronic USA, INC. | $115.98 | 2019 | |
| Medical Device Business Services, INC. | $93.16 | 2025 | Velys |
| Depuy Synthes Sales INC. | $83.58 | 2019-2024 | Trumatch |
| Augmedics INC. | $52.23 | 2024 | Xvision |
| Arteriocyte Medical Systems, INC. | $18.13 | 2023 | Magellan |
| Nx Development Corp. | $17.80 | 2019 | |
| Abbvie INC. | $16.44 | 2025 | |
| Ethicon US, LLC | $14.57 | 2025 | Surgiflo Hemostatic Matrix, Surgicel Nu-Knit, Vistaseal |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$710,997.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.